DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Gilead Sciences, Inc. today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company's injectable HIV-1 capsid inhibitor, ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $130 from $123 and keeps an Overweight rating on the ...

WeDriveU Customers Named Best Workplaces and Best Universities for Commuters in 2025 WeDriveU logo Annual award program honors emplo ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Forty years after the release of Atwood’s seminal novel, we are witnessing the echoes of real-life horror stories that ...

What better place to start the Legislature’s grand dream to make Florida Mississippi again than a breathless announcement ...

DelveInsight's Interferons Market Insights report provides the current and forecast market analysis, individual leading ...

Shares of Gilead Sciences Inc. GILD shed 1.08% to $114.74 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.22% to 5,778.15 ...

The Global Fund to Fight AIDS, Tuberculosis and Malaria says it will fund the rollout of the twice-yearly anti-HIV jab, ...